Live Breaking News & Updates on Ontinued Rog Ch0012032048

Stay updated with breaking news from Ontinued rog ch0012032048. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

New data from the phase II CITYSCAPE trial show encouraging results with Roche's novel anti-TIGIT tiragolumab plus Tecentriq

After 2.5 years median follow-up, pre-planned exploratory analyses in the PD-L1-high population show clinically meaningful results, with overall survival not yet reached and continued progression-free. | December 10, 2021 ....

Roche Holding Ag Stock Exchange , Press Release , Ontinued Rog Ch0012032048 ,